{
    "nctId": "NCT00470249",
    "briefTitle": "Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Overall response rate (complete or partial response)",
    "eligibilityCriteria": "Inclusion criteria:\n\n* DISEASE CHARACTERISTICS: histologically confirmed breast cancer, locally advanced or metastatic disease, recurrent or refractory disease, histological or cytological confirmation required for recurrence in a solitary site\n* Must have received prior anthracycline and taxane as neoadjuvant, adjuvant, or metastatic therapy\n* At least 1 measurable site of disease, defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques or \u2265 10 mm by spiral CT scan\n* Palpable disease allowed, Lesions that have been irradiated in the advanced setting cannot be included as sites of measurable disease\n* No nonmeasurable disease only, including the following:\n* Bone lesions\n* Leptomeningeal disease\n* Ascites\n* Pleural or pericardial effusion\n* Inflammatory breast disease\n* Lymphangitic pulmonary disease\n* Abdominal masses that are not confirmed and followed by imaging techniques\n* Cystic lesions\n* No HER2-positive disease, defined as 3+ by IHC OR positive by FISH or chromogenic in situ hybridization\n* Hormone receptor status not specified\n* PATIENT CHARACTERISTICS:\n* Male or female, Menopausal status not specified, ECOG performance status 0-1, Estimated life expectancy \u2265 12 weeks, Not pregnant or nursing, fertile patients must use effective contraception during and for 3 months after completion of study therapy\n* ANC \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 9 g/dL\n* ALT or AST \\< 2.5 times upper limit of normal (ULN)\n* Bilirubin normal\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Creatinine \u2264 1.25 times ULN OR creatinine clearance \\> 40 mL/min\n* Calcium \u2264 1.2 times ULN\n* No concurrent serious medical or psychiatric illness, including any serious active infection incompatible with the study\n* No other primary malignancy except carcinoma in situ of the cervix, adequately treated nonmelanomatous skin cancer, or any other malignancy previously treated \u2265 5 years ago with no evidence of recurrence\n* No peripheral neuropathy \u2265 grade 2\n* PRIOR CONCURRENT THERAPY (See Disease Characteristics):\n* Recovered from prior chemotherapy\n* Prior hormonal therapy or immunotherapy allowed\n* Antitumoral hormonal therapy must be discontinued prior to study entry\n* More than 4 weeks since prior radiotherapy and recovered\n* No prior radiotherapy to the whole pelvis or to \u2265 25% of the bone marrow\n* No prior gemcitabine hydrochloride, cisplatin, or carboplatin\n* No other cytotoxic chemotherapy for 21 days before and for 14 days after completion of study therapy\n* More than 30 days since prior treatment with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry\n* Bisphosphonate therapy may not be initiated or discontinued within 4 weeks of study entry\n* No more than 1 prior course of chemotherapy for metastatic disease\n* Prior chemotherapy in the adjuvant setting allowed\n* Concurrent palliative radiotherapy to existing painful lesions (soft tissue or bone) allowed\n* New bone pain requiring radiotherapy \\> 4 weeks after first study treatment considered disease progression\n* New pain in a soft tissue lesion without other objective changes may be irradiated provided \u2265 1 other site of nonirradiated measurable disease exists\n* No other concurrent anticancer treatment\n* No concurrent tamoxifen citrate, aromatase inhibitors, or progestagens",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}